GHRH (1–44) vs GHRP-2
Both GHRH (1–44) and GHRP-2 are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
GHRH (1–44)
Evidence AGrowth Hormone Releasing Hormone, full sequence
The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.
View full GHRH (1–44) profile →GHRP-2
Evidence BGrowth Hormone Releasing Peptide 2
A potent synthetic ghrelin-mimetic GH secretagogue. Drives strong GH spikes but raises cortisol and prolactin more than newer alternatives like Ipamorelin.
View full GHRP-2 profile →Side-by-Side
| Attribute | GHRH (1–44) | GHRP-2 |
|---|---|---|
| Evidence Grade | A | B |
| FDA Status | FDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limited | Not FDA-approved — research compound; previously studied as growth hormone deficiency diagnostic |
| Typical Dose | 1 mcg/kg IV (diagnostic test) | 100–300 mcg, 1–3 times daily (subcutaneous) |
| Clinics Indexed | 22 | 86 |
| Categories | growth-hormone | growth-hormone, anti-aging |
Key reported benefits — GHRH (1–44)
- ✓Endogenous GH stimulation
- ✓Diagnostic GH testing
Key reported benefits — GHRP-2
- ✓Strong GH release
- ✓Appetite stimulation
- ✓Muscle recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.